Orvell C
J Immunol. 1984 May;132(5):2622-9.
Mouse hybridomas producing antibodies against structural proteins of mumps virus were established by fusion of FO or SP 2/0 myeloma cells with spleen cells from BALB/c mice immunized with purified preparations of egg-grown mumps virus. Ascites fluids collected after i.p. inoculation of mice were characterized by different serologic tests. By immune precipitation tests with [35S]methionine-labeled mumps virus polypeptides, 17 clones were found to produce antibodies against the nucleocapsid protein (NP), 11 against the polymerase (P) protein, 10 against the membrane (M) protein, 12 against the fusion (F) protein, and 24 against the hemagglutinin-neuraminidase (HN) protein. Competitive binding enzyme-linked immunosorbent assay (ELISA) tests were performed to determine the reactivity of the monoclonal antibodies with different antigenic sites of each structural component. The monoclonal antibodies directed against the NP, P, and M proteins identified a minimum of 10, 10, and 9 separate antigenic sites, respectively. The 12 clones directed against F were directed against a minimum of eight separate antigenic determinants. These antibodies did not neutralize the infectivity of the virus either in the absence or presence of anti-gamma-globulin. Only low capacity to block hemolysis (HL) activity of the virus was detected in clones directed against three of the eight antigenic sites. Based on their serologic reactivity, the 24 clones directed against the HN protein could be divided into four groups. The first group of clones could not inhibit any biologic activity of the protein. The second group consisted of two clones that blocked HL but did not block hemagglutination (HA) or neuraminidase (NA) activity. The third group, which included five clones, blocked HA, NA, and HL activity of the virus and had high neutralizing capacity. These clones were directed against three distinct antigenic sites. Two of the clones directed against one antigenic site could block NA activity only when a large substrate, fetuin, was used, but not when a small substrate, neuraminlactose, was used in the test. The fourth group included five clones that could block NA but not HA activity of the virus. These clones could neutralize the infectivity of the virus and had high capacity to block HL activity. In blocking experiments, all these antibodies reacted with one antigenic site. The reaction of all clones was tested in ELISA with four different strains of mumps virus. Each strain had unique antigenic sites. Variations were found in four, three, and three different antigenic sites of the NP, P, and HN proteins, respectively.
通过将FO或SP 2/0骨髓瘤细胞与用鸡胚培养的腮腺炎病毒纯化制剂免疫的BALB/c小鼠的脾细胞融合,建立了产生抗腮腺炎病毒结构蛋白抗体的小鼠杂交瘤。对经腹腔接种小鼠后收集的腹水进行了不同的血清学检测。通过用[35S]甲硫氨酸标记的腮腺炎病毒多肽进行免疫沉淀试验,发现17个克隆产生抗核衣壳蛋白(NP)的抗体,11个产生抗聚合酶(P)蛋白的抗体,10个产生抗膜(M)蛋白的抗体,12个产生抗融合(F)蛋白的抗体,24个产生抗血凝素神经氨酸酶(HN)蛋白的抗体。进行竞争结合酶联免疫吸附测定(ELISA)试验,以确定单克隆抗体与每个结构成分不同抗原位点的反应性。针对NP、P和M蛋白产生的单克隆抗体分别鉴定出至少10个、10个和9个不同的抗原位点。针对F蛋白的12个克隆针对至少8个不同的抗原决定簇。这些抗体在不存在或存在抗γ球蛋白的情况下均不能中和病毒的感染性。在针对8个抗原位点中的3个的克隆中,仅检测到低水平的阻断病毒溶血(HL)活性的能力。根据血清学反应性,针对HN蛋白的24个克隆可分为4组。第一组克隆不能抑制该蛋白的任何生物学活性。第二组由2个克隆组成,它们阻断HL但不阻断血凝(HA)或神经氨酸酶(NA)活性。第三组包括5个克隆,它们阻断病毒的HA、NA和HL活性,并具有高中和能力。这些克隆针对3个不同的抗原位点。针对一个抗原位点的2个克隆中,只有在使用大底物胎球蛋白时才能阻断NA活性,而在试验中使用小底物神经氨酸乳糖时则不能。第四组包括5个克隆,它们可以阻断病毒的NA但不阻断HA活性。这些克隆可以中和病毒的感染性,并具有高阻断HL活性的能力。在阻断实验中,所有这些抗体都与一个抗原位点发生反应。用4种不同的腮腺炎病毒株在ELISA中检测了所有克隆的反应。每种病毒株都有独特的抗原位点。在NP、P和HN蛋白的4个、3个和3个不同抗原位点中分别发现了变异。